MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Search

Allogene Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

1.3 4.84

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.24

Max

1.33

Pagrindiniai rodikliai

By Trading Economics

Pajamos

8.8M

-51M

Pelno marža

272,450

Darbuotojai

226

EBITDA

-335K

-57M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+658.06% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

56M

282M

Ankstesnė atidarymo kaina

-3.54

Ankstesnė uždarymo kaina

1.3

Naujienos nuotaikos

By Acuity

28%

72%

69 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Allogene Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-02 23:30; UTC

Karštos akcijos

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2025-10-02 21:21; UTC

Uždarbis

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

2025-10-03 00:00; UTC

Įsigijimai, susijungimai, perėmimai

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2025-10-02 23:40; UTC

Rinkos pokalbiai

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2025-10-02 23:39; UTC

Rinkos pokalbiai

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2025-10-02 23:00; UTC

Rinkos pokalbiai

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2025-10-02 22:54; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Scales's JV Buyout Lauded by Bull -- Market Talk

2025-10-02 22:54; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-02 22:46; UTC

Rinkos pokalbiai

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2025-10-02 22:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-02 21:17; UTC

Įsigijimai, susijungimai, perėmimai

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2025-10-02 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-10-02 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-02 20:49; UTC

Įsigijimai, susijungimai, perėmimai

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2025-10-02 20:00; UTC

Įsigijimai, susijungimai, perėmimai

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2025-10-02 19:20; UTC

Rinkos pokalbiai

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2025-10-02 19:10; UTC

Rinkos pokalbiai

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2025-10-02 19:04; UTC

Rinkos pokalbiai

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2025-10-02 18:45; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2025-10-02 18:45; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2025-10-02 18:43; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Akcijų palyginimas

Kainos pokytis

Allogene Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

658.06% į viršų

12 mėnesių prognozė

Vidutinis 9.4 USD  658.06%

Aukščiausias 14 USD

Žemiausias 7 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Allogene Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

7

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.18 / 1.69Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

69 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat